In a Honduran city, biotechs create gene therapy cocktails to fight aging
By Frankie Fattorini,
Pharmaceutical Technology
| 12. 02. 2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a clinical site in Próspera to study the cognitive and health benefits with its circular RNA therapy in a Phase I trial (NCT07216781), in addition to a site in Austin, Texas, where it is headquartered. Last year, the longevity-focused biotech Unlimited Bio got incorporated in the city. Its CEO Ivan Morgunov told Pharmaceutical Technology that Próspera’s lax regulations foster the company’s lofty goal to create a regimen of gene therapies and other treatments aimed at addressing what he sees as the problem of human ageing.
However, industry experts are not yet convinced. Fellow gene therapy developers question both the scientific plausibility of fighting ageing through combinatorial gene therapies and whether ageing can be pathologised at all. At the same time, it is unknown if such biotechs can gather data acceptable to regulatory agencies like the US Food and Drug Administration...
Related Articles
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By Amy Feldman, Forbes | 02.17.2026
"Jennifer Doudna" by Duncan Hull for the Royal Society via Wikimedia Commons licensed under CC by SA 3.0
Soon after KJ Muldoon was born in August 2024, he was lethargic and wouldn’t eat. His worried doctors realized his ammonia...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...